News
Business
People
Technology
Training
Buyer's Guide Products
Sign In
Jobs
Podcast
Video
Events
Training Directory
Subscribe
Site Map
2022
February
26
Reata Pharmaceuticals Receives Complete Response Letter From The FDA for Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome
Reata Pharmaceuticals Receives Complete Response Letter From The FDA for Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome
Page 1 of 1